Previous studies have shown that mutations in genes including PIK3CA, TP53, ESR1, and ERBB2 can be used as prognostic biomarkers in BC, and these biomarkers can assist the implementation of personalized therapy for BC patients [29]. Here, ERBB2 is linked to breast cancer.